Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.90 |
| ▸ | FASN | P49327 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 12/20 | 0.46 |
| ▸ | ACACA | Q13085 | 12/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31519 | 0.95 | F2RL1 (1.00) | F2RL1FASNMEN1HPGDTSHR | |
| SCHEMBL15071152 | 0.89 | F2RL1 (0.75) | F2RL1FASNMEN1HPGDTSHR | |
| SCHEMBL15071158 | 0.87 | F2RL1 (0.73) | F2RL1MEN1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL31518 | 0.87 | F2RL1 (0.72) | F2RL1FASNMEN1HPGDKMT2A | |
| SCHEMBL15071100 | 0.85 | F2RL1 (0.77) | F2RL1MEN1HPGDTSHRKMT2A | |
| SCHEMBL31533 | 0.85 | F2RL1 (0.82) | F2RL1FASNKMT2AACACBACACA | |
| SCHEMBL15074832 | 0.84 | F2RL1 (0.69) | F2RL1HPGDSMN1; SMN2ACACBACACA | |
| SCHEMBL15071143 | 0.84 | F2RL1 (0.74) | F2RL1MEN1HPGDTSHRKMT2A | |
| SCHEMBL15050009 | 0.84 | F2RL1 (0.68) | F2RL1HPGDSLC2A1 | |
| SCHEMBL15071160 | 0.83 | F2RL1 (0.67) | F2RL1MEN1HPGDTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO.,LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO.,LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| WO-2012026765-A2 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | (주)네오팜 (KR) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | F2RL1, F2R, FPR2 | F2RL1 1/4885FASN 2594/4885MEN1 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.